Syntara (SNT) Investor presentation summary

Investment highlights

• Clinical-stage drug developer with 43% institutional backing and a strong patent portfolio.

• Funded into 2027 with $12.3m cash and $11.5m in non-dilutive grants over the last 3 years.

• Three Phase 2 studies in blood cancer with addressable market value over $4.5bn.

• Experienced team with a proven track record in licensing and $100m raised.

• Multiple assets in Phase 2, Phase 1, and preclinical stages.

Financial overview

• Market cap of A$52.2m and enterprise value of A$39.9m as of February 2026.

• Institutional ownership exceeds 43.4%, with major holders including D & A Income Limited and Platinum Investment Management.

• Cash balance of A$12.3m as of December 2025.

Leadership and governance

• Board includes former Merck SVP, CSL executives, and experienced investment professionals.

• CEO with over 30 years in pharma, joined in 2003 and appointed CEO in 2013.